LABORATORIOS FARMACEUTICOS ROVI, S.A. «12345» Page 4 out of 5 15/03/2022 07:52 LABORATORIOS FARMACEUTICOS ROVI, S.A. (LABORATORIOS ROVI) On significant placements in financial instruments Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Register number: 1363 Related to communication no. 1362 dated 14/03/2022 (18:00) 14/03/2022 18:00 LABORATORIOS FARMACEUTICOS ROVI, S.A. (LABORATORIOS ROVI) On significant placements in financial instruments Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Register number: 1362 23/02/2022 08:46 LABORATORIOS FARMACEUTICOS ROVI, S.A. On corporate governance La Sociedad informa sobre los acuerdos adoptados por su Consejo de Administración. Register number: 1320 23/02/2022 08:24 LABORATORIOS FARMACEUTICOS ROVI, S.A. On P&L The Company releases the 2021 financial results presentation Register number: 1319 23/02/2022 08:22 LABORATORIOS FARMACEUTICOS ROVI, S.A. On P&L The Company releases the press release related to the full year 2021 financial results Register number: 1318 22/02/2022 14:47 LABORATORIOS FARMACEUTICOS ROVI, S.A. On share buy-back , stabilisation and treasury stock programmes The Company informs of the end of the share buy-back programme launched as of 3 November 2021, and of the launching of a new share buy-back programme, effective as of 23 February 2022. Register number: 1308 16/02/2022 07:42 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company informs of the expansion of the collaboration that currently exists between ROVI and Moderna for the manufacture of mRNA medicines Register number: 1299 03/11/2021 07:32 LABORATORIOS FARMACEUTICOS ROVI, S.A. On share buy-back , stabilisation and treasury stock programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Register number: 1143 16/07/2021 14:46 LABORATORIOS FARMACEUTICOS ROVI, S.A. On corporate governance Laboratorios Farmacéuticos Rovi, S.A. announces the appointment of Juan López-Belmonte Encina as Chairman of the Board of Directors Register number: 991 22/06/2021 20:07 LABORATORIOS FARMACEUTICOS ROVI, S.A. (LABORATORIOS ROVI) On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Register number: 948 Page 4 out of 5 «12345»
